Rhabdoid Features in Leiomyosarcoma of Soft

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Rhabdoid Features in Leiomyosarcoma of Soft Tissue: With Special Reference to Aggressive Behavior Yumi Oshiro, M.D., Hideki Shiratsuchi, M.D., Yoshinao Oda, M.D., Satoshi Toyoshima, M.D., Masazumi Tsuneyoshi, M.D. Department of Anatomic Pathology, Graduate School of Medical Science, Kyushu University soft tissue with rhabdoid cells showed a tendency The presence of rhabdoid cells has been reported in for poorer prognoses than cases without rhabdoid various types of malignant neoplasms and has been features. On the contrary, retroperitoneal cases did determined to be a predictor of aggressive behavior not. This study indicates that rhabdoid features are of neoplasms regardless of tumor histogenesis. One associated with aggressive biological behavior in hundred and thirteen cases of leiomyosarcoma, se- leiomyosarcoma of the external soft tissue. lected from 1800 soft tissue sarcomas, were re- viewed on hematoxylin and eosin sections, and im- KEY WORDS: Leiomyosarcoma; rhabdoid cells. munohistochemical staining when available, and Mod Pathol 2000;13(11):1211–1218 seven cases with rhabdoid features were retrieved. Clinicopathologic differences were analyzed to Leiomyosarcoma is a relatively rare soft-tissue sar- compare between cases with rhabdoid features and coma, accounting for between 5 and 10% of soft- those without rhabdoid features. In the seven cases tissue sarcomas. They can be divided into groups as with rhabdoid features, two were intra-abdominal, follows: 1) leiomyosarcoma of retroperitoneum and and the others arose in external soft tissues includ- other intra-abdominal sites; 2) leiomyosarcoma of ing muscle, subcutis, and cutis. Patient age ranged deep soft tissue, other than at abdominal sites; 3) from 33 to 84 years, three were female, and four leiomyosarcoma of cutaneous or subcutaneous tis- were male. Tumor size ranged from 3 to 22 cm. sue; 4) leiomyosarcoma of vascular origin. The lo- Clinical evidence showed no differences from those cation is important because it is accurately re- cases without rhabdoid features. Histologically, one flected in the outcome for the patient. Tumor size is of the abdominal cases was epithelioid leiomyosar- also known to be an important prognostic factor. coma. Two of the 7 cases were better subclassified as Histological features of leiomyosarcoma, case by pleomorphic leiomyosarcoma, in which rhabdoid case, show a great variety of patterns and are not cells are diffusely scattered. In cases other than yet recognized as prognostic factors (1–3). those with pleomorphic leiomyosarcomas, foci of Malignant rhabdoid tumor of the kidney is a dis- anaplastic areas were observed, and collections of tinctive clinicopathological entity that is recognized rhabdoid cells were present in those areas. Immu- as a highly aggressive renal tumor of childhood nohistochemical examination of the cases con- (4–6). Extrarenal malignant rhabdoid tumors have firmed myogenic differentiation, and showed rhab- been proposed to exist at several sites, including doid cells being positive for vimentin and desmin in soft parts. However, there have been doubts as to the inclusion bodies, and diffusely so for muscle the existence of such an entity, because of the lack actin in the cytoplasm. After dividing all the cases of of clinicopathologic uniformity among the cases leiomyosarcoma by their location, prognostic anal- (7–23). Furthermore, the presence of rhabdoid cells ysis was performed. Leiomyosarcoma of external has been reported in various types of specific ma- lignant neoplasms, either mesenchymal or epithe- lial (24–37). Despite the degree of differentiation of Copyright © 2000 by The United States and Canadian Academy of tumors with a rhabdoid phenotype, these are now Pathology, Inc. VOL. 13, NO. 11, P. 1211, 2000 Printed in the U.S.A. recognized as highly aggressive neoplasms. Only a Date of acceptance: June 13, 2000. few examples of leiomyosarcomas have been re- This work was supported in part by a Grant-in-Aid for Cancer Research from the Fukuoka Cancer Society, Fukuoka and a Grant-in-Aid for Gen- ported to show rhabdoid features in the reviews of eral Scientific Research from the Ministry of Education, Science, Sports and Culture (09470052), Tokyo, Japan. malignant rhabdoid tumors of soft tissue (8, 9). In Address reprint requests to: Masazumi Tsuneyoshi, M.D., Department of the current study, we describe seven cases of Anatomic Pathology, Graduate School of Medical Science, Kyushu Uni- versity, 3–1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582 Japan; e-mail: leiomyosarcoma with rhabdoid features and show a [email protected]; fax: 81-92-642-5968. relationship to aggressive biological behavior, espe- 1211 cially in cases of leiomyosarcoma arising in an ex- ranged from 11 to 89 years (mean, 57) in all cases, ternal soft tissue site. 24 to 84 (mean, 58) in retroperitoneal cases, 11 to 89 (mean, 54) in external soft tissue cases, and showed no significant differences. Male-to-female ratio was MATERIALS AND METHODS 53:78 (unknown, 2), 36:49 in retroperitoneal cases, One hundred and thirty-three cases of leiomyo- and 17:29 in external soft tissue cases. Tumor sizes sarcoma were reviewed, taken from the 1800 cases ranged from 5 to 35 cm (mean, 13.8) in retroperi- of soft-tissue sarcoma in the files of the Department toneal cases and 1 to 25 (mean, 5.8) in external soft of Anatomic Pathology at Kyushu University, Japan. tissue cases including superficial cases (mean, 3.8) Leiomyosarcomas originating in the perineal re- and deep external soft tissue cases (mean, 9.2). gion, vessels, or intestinal wall were excluded from Significant differences were observed between the this study. Cases containing significant extent of tumor sizes of abdominal cases and those of super- tumor cells with rhabdoid features, despite rela- ficial cases (P Ͻ 0.001), and also between deep tively low total fraction of cells or only focal collec- external soft tissue cases and superficial cases (P ϭ tions, are recognized as cases with rhabdoid fea- 0.002557). ture. Cases containing only a few rhabdoid-like Seven cases showed rhabdoid features. A sum- cells are not included in the cases. Seven cases with mary of the clinicopathological data of the cases rhabdoid features were retrieved from the files. with rhabdoid features is listed in Table 2. In these Representative sections from the available cases cases, patient age ranged from 33 to 84 years, three were selected for immunohistochemistry. The im- were female, and four were male. Tumor size munoperoxidase staining was done using the ranged from 3 to 22 cm. Patient ages and tumor streptavidin biotin-peroxidase method (Histofine sizes showed no differences between cases with SAB-PO Kit, Nichirei Co, Tokyo, Japan). The anti- rhabdoid features and those without rhabdoid fea- bodies used shown in Table 1. tures, regardless of the tumor site. In 91 of these cases, including six with rhabdoid features, follow-up data was available for analysis. The length of survival was tested by Kaplan-Meier Therapy analysis with both Gehan-Wilcoxon and Peto log- The summary of the therapy in patients with rank tests. rhabdoid features is listed also in Table 2. In patient 1, with an intra-abdominal mass, the tumor was easily resected from the omentum. The other with RESULTS an intra-abdominal mass, patient 2, showed no in- Clinical Findings vasion to the surrounding organs and was treated by excision. Patient 3, with a subcutaneous tumor, Clinical data of all 133 cases of leiomyosarcoma underwent excision with a required wide surgical were analyzed to compare between cases with rhab- margin. In patient 4, a subcutaneous tumor was doid features and those without rhabdoid features. also excised with a wide margin. Patient 5 had an The cases of leiomyosarcoma constituted 86 cases intramuscular tumor that was easily movable and in retroperitoneum, mesentery or other intra- was excised with the required wide surgical margin abdominal sites (defined as retroperitoneal cases), after preoperative chemotherapy with vincristine, and 47 cases in nonretroperitoneal external soft actinomycin-D, and cyclophosphamide. In patient tissue sites. External soft tissue cases are composed 6, with a tumor arising in the thigh, pulmonary of 34 cases with depth clarified (21 in superficial metastasis was found at presentation and the pa- sites such as subcutis or cutis and 13 in deeper site tient underwent preoperative radiation and chemo- such as fascia and muscle of extremities) and 13 therapy with adriamycin, vincristine, and cyclo- with unknown depths. Details of the location of phosphamide, followed by the excision of the external soft tissue were as follows: 22 cases in tumor arising in the sartorius muscle. In the re- lower extremities, 8 each in upper extremities, limb maining case, of a tumor arising in the buttocks, the girdle, and trunk, and one of the head. Patient age tumor was excised but details are not known. TABLE 1. Monochronal antibodies used Histological Findings Clone Source Dilution The seven cases with rhabdoid features showed a Vimentin V9 DAKO 1:25 great variety of histological features compared with ␣SMA 1A4 SIGMA 1:5000 Muscle actin HHF35 Biomeda 1:200 leiomyosarcomas without rhabdoid features. Three Desmin D33 DAKO 1:100 cases showed well to moderately differentiated Cytokeratin CAM5.2 Becton Dickinson 1:20 leiomyosarcoma, displaying interlacing bundles of SMA, smooth muscle actin. elongated spindle cells with abundant eosinophilic 1212 Modern Pathology TABLE 2. List of cases with rhabdoid features Patient Age Sex Site Size (cm) Therapy Prognosis Histologic finding 1 55 F Abdominal cavity 18 ϫ 9.5 Marginal excision 85 mo. Alive Epithelioid leiomyosarcoma 2 62 F Omentum 13 ϫ 10 Marginal excision Unknown Moderately differentiated 3 53 F Thigh, subcutis 8 ϫ 6 Wide excision 19 mo. DOD Moderately differentiated 4 76 M Buttock, subcutis 6 ϫ 5 Wide excision 27 mo. Alive Pleomorphic, myxoid MFH like area 5 33 M Thigh muscle 5 ϫ 6 Wide excision after chemotherapy 45 mo.
Recommended publications
  • Uterine Sarcomas: a Review

    Uterine Sarcomas: a Review

    ARTICLE IN PRESS YGYNO-973334; No. of pages: 9; 4C: 3, 6 Gynecologic Oncology xxx (2009) xxx–xxx Contents lists available at ScienceDirect Gynecologic Oncology journal homepage: www.elsevier.com/locate/ygyno Review Uterine sarcomas: A review Emanuela D'Angelo, Jaime Prat ⁎ Department of Pathology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Sant Antoni M. Claret, 167, 08025 Barcelona, Spain article info abstract Article history: Objective. Uterine sarcomas are rare tumors that account for 3% of uterine cancers. Their histopathologic Received 29 June 2009 classification was revised by the World Health Organization (WHO) in 2003. A new staging system has been Available online xxxx recently designed by the International Federation of Gynecology and Obstetrics (FIGO). Currently, there is no consensus on risk factors for adverse outcome. This review summarizes the available clinicopathological data Keywords: on uterine sarcomas classified by the WHO diagnostic criteria. Uterine sarcomas Methods. Medline was searched between 1976 and 2009 for all publications in English where the studied Leiomyosarcoma population included women diagnosed of uterine sarcomas. Endometrial stromal sarcoma fi Undifferentiated endometrial sarcoma Results. Since carcinosarcomas (malignant mixed mesodermal tumors or MMMT) are currently classi ed Adenosarcoma as metaplastic carcinomas, leiomyosarcomas remain the most common uterine sarcomas. Exclusion of Carcinosarcoma several histologic variants of leiomyoma, as well as “smooth muscle tumors of uncertain malignant potential,” frequently misdiagnosed as sarcomas, has made apparent that leiomyosarcomas are associated with poor prognosis even when seemingly confined to the uterus. Endometrial stromal sarcomas are indolent tumors associated with long-term survival. Undifferentiated endometrial sarcomas exhibiting nuclear pleomorphism behave more aggressively than tumors showing nuclear uniformity.
  • Mr Leiomyoma Vs Leiomyosarcoma

    Mr Leiomyoma Vs Leiomyosarcoma

    2 0 SCBT· MR 1 LEIOMYOMA VS LEIOMYOSARCOMA 5 Susan M. Ascher, MD Professor & Co-Director of Abdominal Imaging Georgetown University Hospital, Washington, DC T2-W MRI: Normal Uterus, Leiomyoma and Leiomyosarcoma NORMAL LEIOMYOMA LEIOMYOSARCOMA LEIOMYOMA or LEIOMYOSARCOMA LEIOMYOMA LEIOMYOSARCOMA LEIOMYOMA or LEIOMYOSARCOMA LEIOMYOMA LEIOMYOSARCOMA LEIOMYOMA or LEIOMYOSARCOMA LEIOMYOMA LEIOMYOSARCOMA DEGENERATED LEIOMYOMA vs LEIOMYOSARCOMA Distinguishing the two can be challenging Laparoscopic Power Morcellators • Hysterectomy • Myommectomy Prognosis is significantly worse in women who had leiomyosarcomas morcellated than women who underwent standard abdominal hysterectomy Park JY, et al. Gynecol Oncol 2011; 122:255-259. Perri T, et al. Int J Gyencol Cancer 2009; 19:257-260 DEGENERATED LEIOMYOMA vs LEIOMYOSARCOMA Distinguishing the two can be challenging 4/17/14: FDA safety warning on LPM for hysterectomy & myomectomy • Prev of unsuspected uterine sarcoma: 1 in 352 • Prev of unsuspected uterine LMS: 1 in 498 • Upstaging sarcoma 1 in 7000 Pritts et al (open source) 7/10 -11/14: FDA OB-GYN Devices Panel FDA: Quantitative Assessment of the Prevalence of Unsuspected Uterine Sarcoma in Women undergoing Treatment of Uterine Fibroids. Summary and Key Findings http://www.fda.gov/downloads/MedicalDevices/Safety/AlertsandNotices/UCM393589. 7.11.14: “Fate of Uterine Device Now in Hands of FDA: Panel's Recommendations Run From Outright Ban to 'Black Box' Warning to Limited Use” Ethicon voluntarily suspend sales and recalls devices worldwide 9.22.14: “Gynecologists Resist FDA Over Popular Surgical Tool: Doctors Continue to Use Morcellators Months After Regulator Warned They Can Spread Undetected Cancer” 11.24.2014: FDA Black Box Warning & IIE “Warning Prompts Shift in Surgeries on Women” A Yale University study found that 84% of gynecological surgeons at large U.S.
  • A Rare Presentation of Benign Brenner Tumor of Ovary: a Case Report

    A Rare Presentation of Benign Brenner Tumor of Ovary: a Case Report

    International Journal of Reproduction, Contraception, Obstetrics and Gynecology Periasamy S et al. Int J Reprod Contracept Obstet Gynecol. 2018 Jul;7(7):2971-2974 www.ijrcog.org pISSN 2320-1770 | eISSN 2320-1789 DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20182920 Case Report A rare presentation of benign Brenner tumor of ovary: a case report Sumathi Periasamy1, Subha Sivagami Sengodan2*, Devipriya1, Anbarasi Pandian2 1Department of Surgery, 2Department of Obstetrics and Gynaecology, Government Mohan Kumaramangalam Medical College, Salem, Tamil Nadu, India Received: 17 April 2018 Accepted: 23 May 2018 *Correspondence: Dr. Subha Sivagami Sengodan, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Brenner tumors are rare ovarian tumors accounting for 2-3% of all ovarian neoplasms and about 2% of these tumors are borderline (proliferating) or malignant. These tumors are commonly seen in 4th-8th decades of life with a peak in late 40s and early 50s. Benign Brenner tumors are usually small, <2cm in diameter and often detected incidentally during surgery or on pathological examination. Authors report a case of a large, calcified benign Brenner tumor in a 55-year-old postmenopausal woman who presented with complaint of abdominal pain and mass in abdomen. Imaging revealed large complex solid cystic pelvic mass -peritoneal fibrosarcoma. She underwent laparotomy which revealed huge Brenner tumor weighing 9kg arising from left uterine cornual end extending up to epigastric region.
  • Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?

    Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?

    cancers Review Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types? Wout De Wispelaere 1 , Daniela Annibali 1,2 , Sandra Tuyaerts 1,3 , Diether Lambrechts 4,5 and Frédéric Amant 1,6,7,* 1 Department of Oncology, KU Leuven (University of Leuven) and Leuven Cancer Institute (LKI), 3000 Leuven, Belgium; [email protected] (W.D.W.); [email protected] (D.A.); [email protected] (S.T.) 2 Division of Oncogenomics, Antoni Van Leeuwenhoek—Netherlands Cancer Institute (AvL-NKI), 1066 CX Amsterdam, The Netherlands 3 Laboratory of Medical and Molecular Oncology (LMMO), Department of Medical Oncology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), 1090 Brussels, Belgium 4 Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven (University of Leuven), 3000 Leuven, Belgium; [email protected] 5 VIB Center for Cancer Biology, Flemish Institute for Biotechnology (VIB), 3000 Leuven, Belgium 6 Centre for Gynecologic Oncology Amsterdam (CGOA), Antoni Van Leeuwenhoek—Netherlands Cancer Institute, University Medical Center (UMC), 1066 CX Amsterdam, The Netherlands 7 Department of Obstetrics and Gynecology, University Hospitals Leuven (UZ Leuven), 3000 Leuven, Belgium * Correspondence: [email protected] Simple Summary: Immune checkpoint blockade (ICB) has emerged as a very promising therapeutic option for patients, demonstrating unprecedented, durable responses in several difficult-to-treat Citation: De Wispelaere, W.; cancers. Despite research indicating a strong potential for ICB in uterine leiomyosarcomas (uLMSs), a Annibali, D.; Tuyaerts, S.; Lambrechts, clinical trial assessing response to ICB monotherapy in uLMSs showed no clinical benefit. Resistance D.; Amant, F. Resistance to Immune to ICB has been studied extensively in a variety of tumor types, but the resistance mechanisms Checkpoint Blockade in Uterine explaining the lack of response to ICB in uLMSs remain largely unexplored.
  • Soft Tissue Cytopathology: a Practical Approach Liron Pantanowitz, MD

    Soft Tissue Cytopathology: a Practical Approach Liron Pantanowitz, MD

    4/1/2020 Soft Tissue Cytopathology: A Practical Approach Liron Pantanowitz, MD Department of Pathology University of Pittsburgh Medical Center [email protected] What does the clinician want to know? • Is the lesion of mesenchymal origin or not? • Is it begin or malignant? • If it is malignant: – Is it a small round cell tumor & if so what type? – Is this soft tissue neoplasm of low or high‐grade? Practical diagnostic categories used in soft tissue cytopathology 1 4/1/2020 Practical approach to interpret FNA of soft tissue lesions involves: 1. Predominant cell type present 2. Background pattern recognition Cell Type Stroma • Lipomatous • Myxoid • Spindle cells • Other • Giant cells • Round cells • Epithelioid • Pleomorphic Lipomatous Spindle cell Small round cell Fibrolipoma Leiomyosarcoma Ewing sarcoma Myxoid Epithelioid Pleomorphic Myxoid sarcoma Clear cell sarcoma Pleomorphic sarcoma 2 4/1/2020 CASE #1 • 45yr Man • Thigh mass (fatty) • CNB with TP (DQ stain) DQ Mag 20x ALT –Floret cells 3 4/1/2020 Adipocytic Lesions • Lipoma ‐ most common soft tissue neoplasm • Liposarcoma ‐ most common adult soft tissue sarcoma • Benign features: – Large, univacuolated adipocytes of uniform size – Small, bland nuclei without atypia • Malignant features: – Lipoblasts, pleomorphic giant cells or round cells – Vascular myxoid stroma • Pitfalls: Lipophages & pseudo‐lipoblasts • Fat easily destroyed (oil globules) & lost with preparation Lipoma & Variants . Angiolipoma (prominent vessels) . Myolipoma (smooth muscle) . Angiomyolipoma (vessels + smooth muscle) . Myelolipoma (hematopoietic elements) . Chondroid lipoma (chondromyxoid matrix) . Spindle cell lipoma (CD34+ spindle cells) . Pleomorphic lipoma . Intramuscular lipoma Lipoma 4 4/1/2020 Angiolipoma Myelolipoma Lipoblasts • Typically multivacuolated • Can be monovacuolated • Hyperchromatic nuclei • Irregular (scalloped) nuclei • Nucleoli not typically seen 5 4/1/2020 WD liposarcoma Layfield et al.
  • About Soft Tissue Sarcoma Overview and Types

    About Soft Tissue Sarcoma Overview and Types

    cancer.org | 1.800.227.2345 About Soft Tissue Sarcoma Overview and Types If you've been diagnosed with soft tissue sarcoma or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is a Soft Tissue Sarcoma? Research and Statistics See the latest estimates for new cases of soft tissue sarcoma and deaths in the US and what research is currently being done. ● Key Statistics for Soft Tissue Sarcomas ● What's New in Soft Tissue Sarcoma Research? What Is a Soft Tissue Sarcoma? Cancer starts when cells start to grow out of control. Cells in nearly any part of the body can become cancer and can spread to other areas. To learn more about how cancers start and spread, see What Is Cancer?1 There are many types of soft tissue tumors, and not all of them are cancerous. Many benign tumors are found in soft tissues. The word benign means they're not cancer. These tumors can't spread to other parts of the body. Some soft tissue tumors behave 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 in ways between a cancer and a non-cancer. These are called intermediate soft tissue tumors. When the word sarcoma is part of the name of a disease, it means the tumor is malignant (cancer).A sarcoma is a type of cancer that starts in tissues like bone or muscle. Bone and soft tissue sarcomas are the main types of sarcoma. Soft tissue sarcomas can develop in soft tissues like fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues.
  • Homologous Type of Malignant Mixed Mullerian Tumor of the Uterus Presenting As a Cervical Mass

    Homologous Type of Malignant Mixed Mullerian Tumor of the Uterus Presenting As a Cervical Mass

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector CASE REPORT Homologous Type of Malignant Mixed Mullerian Tumor of the Uterus Presenting as a Cervical Mass Umur Kuyumcuoğlu, Ahmet Kale* Department of Obstetrics and Gynecology, Dicle University Medical School, Diyarbakir, Turkey. Malignant mixed Mullerian tumors are composed of a mixture of sarcoma and carcinoma. The carcinomatous element is usually glandular, whereas the sarcomatous element may resemble normal endometrial stroma (homologous or so- called carcinosarcoma). Here, we present a homologous type of malignant mixed Mullerian tumor of the uterus that pre- sented as a cervical mass. We describe a 55-year-old patient who had a cervical mass arising from the uterus. We performed total abdominal hysterectomy and bilateral salpingo-oophorectomy and surgical staging (including (peritoneal washings, suspicious areas or peritoneal surfaces sampled, infracolic omental sampling, pelvic and paraaortic lymph node sampling, and appendectomy). Carcinosarcomas of the uterine cervix are extremely rare, and when a post- menopausal woman with a cervical mass is admitted to the gynecology clinic, the physician should keep in mind that the mass might be a carcinosarcoma. [J Chin Med Assoc 2009;72(10):533–535] Key Words: carcinosarcoma, cervical mass, malignant mixed Mullerian tumors Introduction and pelvic/paraaortic lymphadenectomy are optimal therapy for carcinosarcoma.1,2 Uterine sarcoma is a malignant tumor that arises from Here, we describe an interesting case of carcino- the smooth muscle or connective tissue of the uterus. sarcoma (homologous type of malignant mixed tumor Uterine sarcomas are rare neoplasms of the female of the uterus) that presented as a cervical mass.
  • A Case of Dedifferentiated Leiomyosarcoma of the Uterus Kanae Nosaka1,2, Hiroaki Komatsu3, Tetsuro Oishi3, Yasushi Horie2, Tasuku Harada3 and Yoshihisa Umekita1*

    A Case of Dedifferentiated Leiomyosarcoma of the Uterus Kanae Nosaka1,2, Hiroaki Komatsu3, Tetsuro Oishi3, Yasushi Horie2, Tasuku Harada3 and Yoshihisa Umekita1*

    Nosaka et al. Int J Pathol Clin Res 2016, 2:049 Volume 2 | Issue 4 International Journal of ISSN: 2469-5807 Pathology and Clinical Research Case Report: Open Access A Case of Dedifferentiated Leiomyosarcoma of the Uterus Kanae Nosaka1,2, Hiroaki Komatsu3, Tetsuro Oishi3, Yasushi Horie2, Tasuku Harada3 and Yoshihisa Umekita1* 1Division of Organ Pathology, Department of Pathology, Tottori University, Japan 2Division of Anatomic Pathology, Tottori University Hospital, Japan 3Division of Reproductive - Perinatal Medicine and Gynecologic Oncology, Department of surgery, Tottori University, Japan *Corresponding author: Yoshihisa Umekita, MD, PhD, Division of Organ Pathology, Department of Pathology, Faculty of Medicine, Tottori University, 86 Nishicho, Yonago, Tottori 683-8503, Japan, E-mail: [email protected] Abstract Case Report Dedifferentiation of leiomyosarcoma is a rare phenomenon that Clinical history associates pleomorphic histology and loss of smooth muscle differentiation. Although the leiomyosarcoma is well known A 63-year-old multiparous female presented with bloody vaginal sarcoma in the uterus, and the dedifferentiated leiomyosarcoma discharge lasting for 2 months. She had no particular medical history is well recognized in the soft parts, there are only a few reports except for the uterine leioimyoma discovered 13 years before. Her of dedifferentiation of leiomyosarcoma in the uterus. Herein we cervical cytology was negative while endometrial cytology detected present a case of dedifferentiated uterine leiomyosarcoma and atypical cells. There was no elevation of tumor markers (CEA and discuss its relation to the undifferentiated uterine sarcoma. CA19-9) in her serum. Hysteroscopy revealed a smooth-surfaced Keywords massive tumor occupying the uterine cavity. Abdominal MRI revealed 7.7 × 9.4 × 12.4 cm of round mass in the anterior uterine Uterine leiomyosarcoma, Dedifferentiation, Undifferentiated uterine corpus.
  • SNOMED CT Codes for Gynaecological Neoplasms

    SNOMED CT Codes for Gynaecological Neoplasms

    SNOMED CT codes for gynaecological neoplasms Authors: Brian Rous1 and Naveena Singh2 1Cambridge University Hospitals NHS Trust and 2Barts Health NHS Trusts Background (summarised from NHS Digital): • SNOMED CT is a structured clinical vocabulary for use in an electronic health record. It forms an integral part of the electronic care record, and serves to represent care information in a clear, consistent, and comprehensive manner. • The move to a single terminology, SNOMED CT, for the direct management of care of an individual, across all care settings in England, is recommended by the National Information Board (NIB), in “Personalised Health and Care 2020: A Framework for Action”. • SNOMED CT is owned, managed and licensed by SNOMED International. NHS Digital is the UK Member's National Release Centre for the creation of, and delegated authority to licence the SNOMED CT Edition and derivatives. • The benefits of using SNOMED CT in electronic care records are that it: • enables sharing of vital information consistently within and across health and care settings • allows comprehensive coverage and greater depth of details and content for all clinical specialities and professionals • includes diagnosis and procedures, symptoms, family history, allergies, assessment tools, observations, devices • supports clinical decision making • facilitates analysis to support clinical audit and research • reduces risk of misinterpretations of the record in different care settings • Implementation plans for England: • SNOMED CT must be implemented across primary care and deployed to GP practices in a phased approach from April 2018. • Secondary care, acute care, mental health, community systems, dentistry and other systems used in direct patient care must use SNOMED CT as the clinical terminology, before 1 April 2020.
  • The Immunosuppressive Niche of Soft-Tissue Sarcomas Is Sustained

    The Immunosuppressive Niche of Soft-Tissue Sarcomas Is Sustained

    Published OnlineFirst April 24, 2020; DOI: 10.1158/1078-0432.CCR-19-3416 CLINICAL CANCER RESEARCH | PRECISION MEDICINE AND IMAGING The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures A C Lingling Chen1, Teniola Oke1, Nicholas Siegel2, Gady Cojocaru3, Ada J. Tam1, Richard L. Blosser1, Jessica Swailes1, John A. Ligon1, Andriana Lebid4, Carol Morris5, Adam Levin5, Daniel S. Rhee6, Fabian M. Johnston7, Jonathan B. Greer7, Christian F. Meyer8, Brian H. Ladle1, Elizabeth D. Thompson9, Elizabeth A. Montgomery10, Woonyoung Choi11, David J. McConkey12, Robert A. Anders13, Drew M. Pardoll4, and Nicolas J. Llosa1 ABSTRACT ◥ Purpose: Clinical trials with immune checkpoint inhibition in bution diverged. UPS specimens demonstrated diffuse intratumoral sarcomas have demonstrated minimal response. Here, we interro- infiltration of T cells, while rhabdomyosarcomas samples revealed gated the tumor microenvironment (TME) of two contrasting soft- intratumoral T cells that clustered with B cells near perivascular tissue sarcomas (STS), rhabdomyosarcomas and undifferentiated beds, forming tertiary lymphoid structures (TLS). T cells in UPS þ pleomorphic sarcomas (UPS), with differing genetic underpinnings specimens were comprised of abundant CD8 T cells exhibiting and responses to immune checkpoint inhibition to understand the high PD-1 expression, which might represent the tumor reactive mechanisms that lead to response. repertoire. In rhabdomyosarcomas, T cells were limited to TLS, but Experimental Design: Utilizing fresh and formalin-fixed, par- expressed immune checkpoints and immunomodulatory molecules affin-embedded tissue from patients diagnosed with UPS and which, if appropriately targeted, could help unleash T cells into the rhabdomyosarcomas, we dissected the TME by using IHC, flow rest of the tumor tissue.
  • Soft Tissue Sarcoma: an Insight on Biomarkers at Molecular, Metabolic and Cellular Level

    Soft Tissue Sarcoma: an Insight on Biomarkers at Molecular, Metabolic and Cellular Level

    cancers Review Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level Serena Pillozzi 1,* , Andrea Bernini 2, Ilaria Palchetti 3 , Olivia Crociani 4, Lorenzo Antonuzzo 1,4, Domenico Campanacci 5 and Guido Scoccianti 6 1 Medical Oncology Unit, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy; lorenzo.antonuzzo@unifi.it 2 Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy; [email protected] 3 Department of Chemistry Ugo Schiff, University of Florence, Via della Lastruccia 3, 50019 Sesto Fiorentino, Italy; ilaria.palchetti@unifi.it 4 Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134 Florence, Italy; olivia.crociani@unifi.it 5 Department of Health Science, University of Florence, Largo Brambilla 3, 50134 Florence, Italy; domenicoandrea.campanacci@unifi.it 6 Department of Orthopaedic Oncology and Reconstructive Surgery, University of Florence, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy; [email protected] * Correspondence: serena.pillozzi@unifi.it Simple Summary: Soft tissue sarcoma is a rare mesenchymal malignancy. Despite the advancements in the fields of radiology, pathology and surgery, these tumors often recur locally and/or with metastatic disease. STS is considered to be a diagnostic challenge due to the large variety of histologi- Citation: Pillozzi, S.; Bernini, A.; cal subtypes with clinical and histopathological characteristics which are not always distinct. One of Palchetti, I.; Crociani, O.; Antonuzzo, the important clinical problems is a lack of useful biomarkers. Therefore, the discovery of biomarkers L.; Campanacci, D.; Scoccianti, G. Soft that can be used to detect tumors or predict tumor response to chemotherapy or radiotherapy could Tissue Sarcoma: An Insight on help clinicians provide more effective clinical management.
  • Role of Tumor-Associated Macrophages in Sarcomas

    Role of Tumor-Associated Macrophages in Sarcomas

    cancers Review Role of Tumor-Associated Macrophages in Sarcomas Tomohiro Fujiwara 1,2,* , John Healey 2, Koichi Ogura 2, Aki Yoshida 1 , Hiroya Kondo 1, Toshiaki Hata 1, Miho Kure 1 , Hiroshi Tazawa 3,4 , Eiji Nakata 1 , Toshiyuki Kunisada 1 , Toshiyoshi Fujiwara 3 and Toshifumi Ozaki 1 1 Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan; [email protected] (A.Y.); [email protected] (H.K.); [email protected] (T.H.); [email protected] (M.K.); [email protected] (E.N.); [email protected] (T.K.); [email protected] (T.O.) 2 Department of Surgery, Orthopaedic Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; [email protected] (J.H.); [email protected] (K.O.) 3 Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan; [email protected] (H.T.); [email protected] (T.F.) 4 Center for Innovative Clinical Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan * Correspondence: [email protected] Simple Summary: Recent studies have shown the pro-tumoral role of tumor-associated macrophages (TAMs) not only in major types of carcinomas but also in sarcomas. Several types of TAM-targeted drugs have been investigated under clinical trials, which may represent a novel therapeutic approach for bone and soft-tissue sarcomas. Citation: Fujiwara, T.; Healey, J.; Ogura, K.; Yoshida, A.; Kondo, H.; Abstract: Sarcomas are complex tissues in which sarcoma cells maintain intricate interactions with Hata, T.; Kure, M.; Tazawa, H.; their tumor microenvironment.